News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
97,279 Results
Type
Article (5544)
Company Profile (10)
Press Release (91725)
Multimedia
Podcasts (10)
Webinars (5)
Section
Business (39209)
Career Advice (354)
Deals (7012)
Drug Delivery (17)
Drug Development (8579)
Employer Resources (29)
FDA (1384)
Job Trends (1748)
News (55645)
Policy (3867)
Tag
Academia (257)
Accelerated approval (1)
Adcomms (1)
Allergies (9)
Alliances (5286)
ALS (8)
Alzheimer's disease (148)
Antibody-drug conjugate (ADC) (22)
Approvals (1386)
Artificial intelligence (32)
Autoimmune disease (9)
Automation (3)
Bankruptcy (65)
Best Places to Work (1425)
BIOSECURE Act (2)
Biosimilars (14)
Biotechnology (11)
Bladder cancer (4)
Brain cancer (3)
Breast cancer (46)
Cancer (278)
Cardiovascular disease (10)
Career advice (310)
Career pathing (2)
CAR-T (23)
Cell therapy (71)
Cervical cancer (2)
Clinical research (6936)
Collaboration (130)
Compensation (27)
Complete response letters (3)
COVID-19 (322)
CRISPR (3)
C-suite (96)
Cystic fibrosis (20)
Data (260)
Denatured (2)
Depression (5)
Diabetes (53)
Diagnostics (775)
Digital health (5)
Diversity, equity & inclusion (10)
Drug discovery (25)
Drug pricing (12)
Drug shortages (5)
Duchenne muscular dystrophy (30)
Earnings (17021)
Editorial (13)
Employer branding (1)
Employer resources (27)
Events (10761)
Executive appointments (318)
FDA (1569)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Funding (152)
Gene editing (13)
Gene therapy (46)
GLP-1 (127)
Government (541)
Grass and pollen (1)
Guidances (33)
Healthcare (2918)
Huntington's disease (3)
IgA nephropathy (6)
Immunology and inflammation (22)
Indications (2)
Infectious disease (347)
Inflammatory bowel disease (34)
Influenza (10)
Intellectual property (26)
Interviews (43)
IPO (3022)
IRA (6)
Job creations (344)
Job search strategy (276)
Kidney cancer (2)
Labor market (8)
Layoffs (59)
Leadership (3)
Legal (1027)
Liver cancer (6)
Lung cancer (26)
Lymphoma (15)
Machine learning (1)
Management (7)
Manufacturing (67)
MASH (18)
Medical device (2057)
Medtech (2058)
Mergers & acquisitions (4157)
Metabolic disorders (114)
Multiple sclerosis (9)
NASH (3)
Neurodegenerative disease (17)
Neuropsychiatric disorders (4)
Neuroscience (220)
NextGen: Class of 2025 (940)
Non-profit (413)
Now hiring (3)
Obesity (51)
Opinion (48)
Ovarian cancer (17)
Pain (20)
Pancreatic cancer (6)
Parkinson's disease (17)
Partnered (1)
Patents (42)
Patient recruitment (16)
Peanut (4)
People (16472)
Pharmaceutical (10)
Pharmacy benefit managers (5)
Phase I (2229)
Phase II (3251)
Phase III (2406)
Pipeline (278)
Policy (26)
Postmarket research (158)
Preclinical (818)
Press Release (17)
Prostate cancer (16)
Psychedelics (7)
Radiopharmaceuticals (66)
Rare diseases (58)
Real estate (533)
Recruiting (15)
Regulatory (2631)
Reports (14)
Research institute (285)
Resumes & cover letters (44)
Rett syndrome (1)
RSV (4)
Schizophrenia (17)
Series A (40)
Series B (13)
Service/supplier (1)
Sickle cell disease (9)
Special edition (3)
Spinal muscular atrophy (16)
Sponsored (8)
Startups (539)
State (1)
Stomach cancer (1)
Supply chain (17)
Tariffs (4)
The Weekly (8)
Vaccines (99)
Venture capitalists (10)
Weight loss (35)
Women's health (7)
Worklife (2)
Date
Today (17)
Last 7 days (153)
Last 30 days (511)
Last 365 days (5488)
2025 (2009)
2024 (6018)
2023 (6517)
2022 (9021)
2021 (9203)
2020 (8295)
2019 (6445)
2018 (5070)
2017 (4761)
2016 (4458)
2015 (5148)
2014 (3857)
2013 (2911)
2012 (3151)
2011 (3288)
2010 (2945)
Location
Africa (104)
Alabama (6)
Alaska (2)
Arizona (31)
Arkansas (4)
Asia (6561)
Australia (943)
California (960)
Canada (446)
China (84)
Colorado (78)
Connecticut (49)
Delaware (24)
Europe (13756)
Florida (156)
Georgia (41)
Idaho (4)
Illinois (80)
India (2)
Indiana (76)
Japan (29)
Kansas (9)
Kentucky (2)
Maine (5)
Maryland (181)
Massachusetts (633)
Michigan (20)
Minnesota (41)
Missouri (8)
Montana (13)
Nebraska (6)
Nevada (11)
New Hampshire (16)
New Jersey (436)
New Mexico (7)
New York (246)
North Carolina (184)
Northern California (448)
Ohio (40)
Oklahoma (3)
Oregon (2)
Pennsylvania (190)
Puerto Rico (7)
Rhode Island (5)
South America (173)
Southern California (344)
Tennessee (11)
Texas (164)
United States (3694)
Utah (32)
Virginia (14)
Washington D.C. (7)
Washington State (43)
West Virginia (1)
Wisconsin (4)
97,279 Results for "remsleep holdings".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
REMSleep Holdings Inc. Receives 510(K) Clearance on Product
July 10, 2024
·
4 min read
Policy
Remsleep Holdings Inc.'s DeltaWave Mask has received questions from FDA regarding 510k submission (K233415)
RemSleep Holdings Inc., a medical device manufacturer dedicated to forever changing the level of treatment provided to Obstructive Sleep Apnea has received a response to the company’s 510 submission K233415.
January 22, 2024
·
5 min read
BioMidwest
RemSleep Holdings Inc. Issues Letter to Shareholders - Jan 06, 2023
RemSleep Holdings Inc., a medical device manufacturer dedicated to forever changing the level of treatment provided to obstructive sleep apnea patients, provides a corporate update and letter to shareholders from CEO Tom Wood.
January 6, 2023
·
8 min read
BioMidwest
RemSleep Holdings Provides a Corporate Update on Testing
RemSleep Holdings Inc., a medical device manufacturer dedicated to forever improving the level of treatment provided to obstructive Sleep Apnea patients, is pleased to announce that the expected last battery of testing will commence this week for final FDA submission of the company’s signature DeltaWave mask.
November 8, 2022
·
5 min read
BioMidwest
RemSleep Holdings Inc. Commences Trading on OTCQB
RemSleep Holdings Inc. is pleased to announce that the company’s common shares will begin trading on the OTCQB Market as of the opening of the market on , July 27, 2022.
July 27, 2022
·
3 min read
BioMidwest
RemSleep Holdings Inc. Submits Application For Uplisting to OTCQB
RemSleep Holdings Inc, a medical device manufacturer dedicated to forever changing the level of treatment provided to obstructive sleep apnea patients, announced that the company has officially filed its application for OTCQB® status with otcmarkets.com.
June 10, 2022
·
5 min read
Press Releases
Genflow Biosciences PLC Announces Holding(s) in Company
May 12, 2025
·
9 min read
RemSleep Holdings Inc. Announces Acceptance and Approval of the Company’s OTCQB Application
RemSleep Holdings Inc. (OTC PINK: RMSL), a medical device manufacturer dedicated to forever changing the level of treatment provided to obstructive Sleep Apnea patients, announced today that the company has officially received approval to be uplisted to OTCQB® status with otcmarkets.com.
July 12, 2022
·
4 min read
BioMidwest
RemSleep Holdings Inc. Engages New Senior Director for Regulatory Compliance and New Regulatory Testing Company
RemSleep Holdings Inc. announces the company has formally retained a new Senior Director for Regulatory Compliance and Regulatory submissions to gain FDA clearance to market the company’s medical device respiratory products.
July 22, 2022
·
7 min read
Immunology and inflammation
Vyne Crashes After Safety Signal in Dogs Puts Hold on Clinical Trial of Plaque Psoriasis
The hold, placed by the FDA on an early-stage clinical trial of an experimental BET inhibitor, stems from a recent observation of testicular toxicity in canines given the treatment.
April 25, 2025
·
2 min read
·
Tristan Manalac
1 of 9,728
Next
